Has Mary Skiba, DO received payments from drug or device companies?

Yes. Drug and device makers reported $25,200 in general payments to Mary Skiba, DO across 234 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Skiba, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Skiba, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Skiba, DO

Hematology · Fort Worth, TXNPI 1093765596

Payments from drug & device makers

$25,200in general payments, 2019–2025

Across 234 payments — averaging $107.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$9K
AstraZeneca$5K
Pharmacosmos Therapeutics Inc.$3K
Bristol Myers Squibb$3K
E.r. Squibb & Sons, L.L.C.$2K
GSK$375
plus $4K from 42 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	38	$9,264
AstraZeneca(2 entities)	22	$4,596
Pharmacosmos Therapeutics Inc.	9	$3,015
Bristol Myers Squibb	19	$2,664
E.r. Squibb & Sons, L.L.C.	20	$1,623
GSK	11	$375
AbbVie	12	$355
Incyte Corporation	4	$293
Puma Biotechnology, Inc.	2	$261
Merck	7	$223
Daiichi Sankyo Inc.	9	$184
Astellas Pharma US Inc	4	$179
Takeda Pharmaceuticals U.S.A., Inc.	6	$173
Johnson & Johnson	3	$161
Exelixis Inc.	2	$157
Novartis	7	$140
Verastem, Inc.	2	$132
ADC Therapeutics America, Inc.	2	$128
Beigene USA, Inc.	4	$98
Taiho Oncology, Inc.	4	$88
Sobi, Inc	3	$88
Amgen	5	$85
Apellis Pharmaceuticals, Inc.	1	$84
Teva Pharmaceuticals USA, Inc.	1	$79
Regeneron Healthcare Solutions, Inc.	3	$79
Tempus AI, Inc	3	$75
Pharmaessentia USA Corporation	2	$69
Genmab U.S., Inc.	3	$61
Pharmacyclics LLC, An Abbvie Company	2	$43
Sanofi	2	$43
Genentech USA, Inc.	2	$39
Lilly USA, LLC	2	$36
Beone Medicines USA, Inc.	2	$32
Seagen Inc.	2	$30
Eisai Inc.	1	$26
Gilead	1	$25
Servier Pharmaceuticals LLC	1	$24
Agios Pharmaceuticals, Inc.	1	$21
Immunocore Limited	1	$21
Rigel Pharmaceuticals, Inc.	1	$18
Tactile Systems Technology Inc	1	$16
Stemline Therapeutics Inc.	1	$16
Caris MPI, Inc.	1	$15
Morphosys, US Inc.	1	$14
Epizyme, Inc.	1	$14
Dova Pharmaceuticals	1	$13
Bayer	1	$13
Tolmar Pharmaceuticals, Inc.	1	$11

How this compares

$25,200 in reported general payments places this provider in the 65th percentile of 97 hematology providers in Texas.

See all hematology providers in Texas →

Medicare billing

Part B allowed, 2024

$572,673

Medicare patients

271

Services billed

49,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Fort Worth

Swaminathan IyerHouston$10.1M
Modupe IdowuHouston$8.7M
Jing YeHouston$4.4M
Uday PopatHouston$4.4M
Sunil PatelHouston$3.5M
Arthur FrankelDallas$3.5M
Montaser ShaheenSan Antonio$3.4M
Yesid Alvarado ValeroHouston$3.2M
Roger LyonsSan Antonio$2.8M
Ankit KansagraDallas$2.7M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →